Opthea Has Completed Enrollment In COAST Phase 3 Trial Of Sozinibercept Plus Aflibercept For Wet Age-related Macular Degeneration. Enrollment In ShORe Study Is Expected To Be Completed In Q2 2024, Topline Data From Both Trials Are Expected By Mid-2025

2/14/24 6:17:17 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $OPT alert in real time by email

Get the next $OPT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OPT

Date	Price Target	Rating	Analyst
12/8/2022	$14.00	Buy	H.C. Wainwright
4/26/2022	$25.00	Outperform	SVB Leerink

More analyst ratings

$OPT
Press Releases

Fastest customizable press release news feed in the world

Opthea Appoints Kathy Connell to Board of Directors
Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of Kathy Connell, GAICD, to the Board of Directors (the "Board") as a Non-Executive Director. Ms. Connell's appointment was effective immediately after the Annual General Meeting of the
11/15/24 7:00:48 AM ET
$OPT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Opthea's Wet AMD Program Featured at Ophthalmology Events
17 Congress of the Asia-Pacific Vitreo-Retina Society, November 22 - 24, 2024 Ophthalmology Innovation Summit XIV, November 23, 2024 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Opthea and sozinibercept will be highlighted during two upcoming Ophthalmology conferences. Conference details are as follows: The 17th Congress of the Asia-Pacific Vitreo-Retina Society (APVRS) Session: Rapid Fire 4 – R
11/12/24 7:00:00 AM ET
$OPT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Opthea to Participate in November Investor Conferences
Virtual Bell Potter Healthcare Conference, November 18, 2024 Jefferies London Healthcare Conference, November 19, 2024 MELBOURNE, Australia and PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in two investor conferences in November 2024. Conference details are as follows: Bell Potter Healthcare ConferencePresentation:Monday, November 18, 2024, 3:00 PM AEDT (Virtual)Presenter:Frederic Guerard, Phar
11/4/24 7:00:00 AM ET
$OPT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$OPT
Leadership Updates

Live Leadership Updates

Opthea Appoints Kathy Connell to Board of Directors
Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of Kathy Connell, GAICD, to the Board of Directors (the "Board") as a Non-Executive Director. Ms. Connell's appointment was effective immediately after the Annual General Meeting of the
11/15/24 7:00:48 AM ET
$OPT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025
Parisa Zamiri, MD, PhD, and Tom Reilly respectively appointed CMO and CFO Anand Sundaram appointed Vice President Marketing MELBOURNE, Australia and PRINCETON, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced three senior hires as the Company continues to prepare for the sozinibercept Phase 3 topline data readouts of COAST anticipated in early Q2 calendar year 2025 and ShORe in mid calendar year 2025. "Opthea is at an inflection point with
10/8/24 7:00:00 AM ET
$OPT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board
MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announces the formation of its Medical Advisory Board ("MAB") composed of 10 retina thought leaders from countries around the world including the US, Argentina, Australia, China, France, Germany, and Israel. Chaired by Arshad M. Khanani, MD, MA, FASRS, Chief Medical Advisor of Opthea, the MAB's role is to advise the Company on opportunities to address the unmet medical
7/17/24 7:15:00 AM ET
$OPT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Opthea Has Completed Enrollment In COAST Phase 3 Trial Of Sozinibercept Plus Aflibercept For Wet Age-related Macular Degeneration. Enrollment In ShORe Study Is Expected To Be Completed In Q2 2024, Topline Data From Both Trials Are Expected By Mid-2025

Chat with this insight

Recent Analyst Ratings for
$OPT

$OPT
Press Releases

Fastest customizable press release news feed in the world

Opthea Appoints Kathy Connell to Board of Directors

Opthea's Wet AMD Program Featured at Ophthalmology Events

Opthea to Participate in November Investor Conferences

$OPT
SEC Filings

SEC Form 6-K filed by Opthea Limited

SEC Form 6-K filed by Opthea Limited

SEC Form 6-K filed by Opthea Limited

$OPT
Market Insights

Live Market Insights

Reported Sunday, Opthea Successfully Completes A$55.9M Retail Entitlement Offer, Marking The Final Stage Of A$227.3M Capital Raising

12 Health Care Stocks Moving In Friday's Pre-Market Session

Trading Halt: Halt status updated at 7:00:00 AM ET: Quotation Resumption: News and Resumption Times

$OPT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Opthea Limited

Amendment: SEC Form SC 13G/A filed by Opthea Limited

SEC Form SC 13G/A filed by Opthea Limited (Amendment)

$OPT
Leadership Updates

Live Leadership Updates

Opthea Appoints Kathy Connell to Board of Directors

Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025

Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board

$OPT
Financials

Live finance-specific insights

Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD

$OPT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on Opthea Ltd. with a new price target

SVB Leerink initiated coverage on Opthea Ltd. with a new price target

Opthea Has Completed Enrollment In COAST Phase 3 Trial Of Sozinibercept Plus Aflibercept For Wet Age-related Macular Degeneration. Enrollment In ShORe Study Is Expected To Be Completed In Q2 2024, Topline Data From Both Trials Are Expected By Mid-2025

Chat with this insight

Recent Analyst Ratings for $OPT

$OPT Press Releases

Fastest customizable press release news feed in the world

Opthea Appoints Kathy Connell to Board of Directors

Opthea's Wet AMD Program Featured at Ophthalmology Events

Opthea to Participate in November Investor Conferences

$OPT SEC Filings

SEC Form 6-K filed by Opthea Limited

SEC Form 6-K filed by Opthea Limited

SEC Form 6-K filed by Opthea Limited

$OPT Market Insights

Live Market Insights

Reported Sunday, Opthea Successfully Completes A$55.9M Retail Entitlement Offer, Marking The Final Stage Of A$227.3M Capital Raising

12 Health Care Stocks Moving In Friday's Pre-Market Session

Trading Halt: Halt status updated at 7:00:00 AM ET: Quotation Resumption: News and Resumption Times

$OPT Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Opthea Limited

Amendment: SEC Form SC 13G/A filed by Opthea Limited

SEC Form SC 13G/A filed by Opthea Limited (Amendment)

$OPT Leadership Updates

Live Leadership Updates

Opthea Appoints Kathy Connell to Board of Directors

Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025

Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board

$OPT Financials

Live finance-specific insights

Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD

$OPT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on Opthea Ltd. with a new price target

SVB Leerink initiated coverage on Opthea Ltd. with a new price target

Recent Analyst Ratings for
$OPT

$OPT
Press Releases

$OPT
SEC Filings

$OPT
Market Insights

$OPT
Large Ownership Changes

$OPT
Leadership Updates

$OPT
Financials

$OPT
Analyst Ratings